Prototype test for predicting clinical outcome for melanoma patients

August 15, 2008

Gene signature prognostication of rapid progression from Stage III to Stage IV

Investigators from the Melbourne Center of the international Ludwig Institute for Cancer Research (LICR) and Pacific Edge Biotchnology Ltd today reported that they have developed a test to predict whether a patient will progress rapidly from Stage III melanoma to metastatic Stage IV cancer and death.

More than 70% of patients with Stage III melanoma - melanoma that has spread to the lymph nodes - will typically have a rapid time to progression (TTP) to Stage IV melanoma, and pass away within five years of their diagnosis. However, the remaining <30% of patients will have a slow TTP to Stage IV and will have prolonged survival. Not being able to distinguish between these patient subtypes means that some patients might undergo aggressive, often toxic, treatments unnecessarily. The unpredictable and significant discrepancies in TTP and survival could also cloud the interpretation of results from clinical trials of new melanoma therapies.

The LICR Melbourne team, together with collaborators from Pacific Edge Biotechnology Limited in New Zealand, has developed a prototype test that can distinguish between these two patient subtypes with 85-90% accuracy. However, the team cautions that these findings must be validated in a larger number of patients before the test can be applied routinely as a prognostic tool.

According to the senior author of the study, LICR's Professor Jonathan Cebon, M.D., the predictive test could assist patients and their health care teams in making treatment decisions. Perhaps most importantly, being able to distinguish between the subtypes could have a tremendous impact on the development of new melanoma therapies. "One of the major problems we have in clinical trials for new melanoma therapies is that we can't identify the people who are going to have a slower disease progression no matter what they receive in a clinical trial," says Professor Cebon. "When new treatments are tested it is necessary to show clinical benefit by comparing patients who receive the new therapy with those who do not. Although patients might all have the same type of cancers, there can be big differences in their survival simply because their cancers behave differently - and this may have nothing to do with the treatment. If we are able to identify the good players and the bad players up-front, it becomes a whole lot easier figuring out whether good results are due to the new treatment or not. Most importantly far fewer patients would be needed for the clinical trials. It's partly because we can't clinically identify subtypes of patients that we have to do very large and very expensive trials. And, of course, this increases the time it takes to test the clinical benefit of potential new therapies."

The joint Australian/New Zealand team used microarrays to measure the expression of more than 30,000 genes in lymph node sections taken from 29 patients with Stage III melanoma. There were 2,140 genes differentially expressed in the sections from people who had already had a "poor" outcome (average TTP of just four months) and patients that had had a "good" outcome (average TTP of 40+ months). Using statistical analyses, the team identified 21 genes that could be used to differentiate between the two subtypes of patients in the retrospective analysis. This gene signature was then used to prospectively analyze another 10 patients, with the clinical outcome for nine of the 10 (90%) patients proving to be predicted accurately. The one patient who was incorrectly predicted to have a "good" prognosis did have a rapid TTP to Stage IV. However, this patient went on to have a prolonged survival of six years. The team also applied the test to published data sets and showed they could get a prediction accuracy of 85%, event though data was not available for all 21 genes in the published literature.

This study was conducted under the auspices of the Hilton - Ludwig Cancer Metastasis Initiative. It was led by investigators from: LICR Melbourne Center Austin Health, Melbourne, Australia; Department of Biochemistry, University of Otago, Otago, New Zealand; Pacific Edge Biotechnology Limited, Dunedin, New Zealand, and; Department of Statistics, University of Auckland, Auckland, New Zealand.

Ludwig Institute for Cancer Research

---

---

	Beating Melanoma: A Five-Step Survival Guide (A Johns Hopkins Press Health Book) by Steven Q. Wang (Author) Dr. Steven Q. Wang, a world-renowned skin cancer expert, provides an essential guide for people with melanoma and their families. The book’s unique, practical format approaches the disease in two phases, just as people with melanoma need to do. First comes a step-by-step guide for what Dr. Wang calls the "mad rush" phase—an intense and stressful period from diagnosis to completing initial treatment. Dr. Wang's calm guidance helps readers through this critical time, using an easy to understand plan for ensuring optimal treatment and survival outcomes. Once the mad rush phase is over, the "marathon phase" begins—life resumes its normal shape but with lingering concerns about new melanoma and metastases. Here Dr. Wang addresses common questions about prevention and prognosis. Beating...
	A Melanoma Patient's Survival Guide: Lemons Really Do Make Lemonade: You Just Have to Add a Little Sugar by Sally Welsh (Author) A Melanoma Patient’s Survival guide: Lemons Really Do Make Lemonade is an effort to bring awareness to the subject of melanoma. This insidious disease is being diagnosed in over 50,000 people a year in the United States alone. Melanoma will affect one in seventy-five people in California. That rate goes up each year. Melanoma can be a silent killer. This heart-warming book was written by a survivor of serious melanoma, Sally Welsh. Sally has shared her experience with thousands of people, and has prepared this book with the hope of making your journey a little easier. Her suggestions deal first of all with the questions you need to ask your doctor, before he cuts into you. You need to know about his initial scanning of you, whether he plans to use a “punch” biopsy or a “scrape”...
	Melanoma: Prevention, Detection, and Treatment; Second Edition (Yale University Press Health & Wellness) by Catherine M. Poole (Author), IV DuPont Guerry (Author) The incidence of melanoma has increased by 2000% since 1930, and one person dies each hour from the disease. This cutting-edge guide provides scientifically accurate information patients and their families need in order to understand melanoma and its treatment and to receive vital reassurance. It is also a resource for those who want information about preventing the disease or finding it early when it is most curable. Catherine M. Poole, a melanoma survivor and melanoma patient advocate for many national organizations, and Dr. DuPont Guerry, an internationally renowned melanoma expert, have collaborated to provide current, correct, and easily understood information on the disease. The authors have had first hand contact with a multitude of patients with melanoma, and they understand...
	What You Really Need to Know about Moles and Melanoma (A Johns Hopkins Press Health Book) by Jill R. Schofield (Author), William A. Robinson (Author) Throughout the world, the incidence of malignant melanoma is increasing at an alarming rate. This dramatic rise is largely due to more frequent and prolonged exposure to intense sun, the result of major changes in clothing styles, recreation, and lifestyle (including widespread access to midwinter resort vacations). Significantly, recent scientific studies have shown an increased number of moles on, and a higher rate of melanoma in, people with the greatest sunscreen use, pointing out the mistaken belief that using sunscreen means getting a "safe" tan. The truth is that most sunscreen provides protection from UVB rays—the rays that cause the sunburn you see and feel—but not from UVA rays—the cancer-causing rays that penetrate deeper into the skin.In this book, physicians Jill R....
	The Melanoma Book : A Complete Guide to Prevention and Treatment, Including the Early DetectionSelf-Exam Body Map by Howard L. Kaufman (Author) From the founder and Co-Director of the renowned Columbia University Melanoma Center, the first comprehensive guide to help you prevent—and survive—a diagnosis of melanoma. The fastest rising form of cancer worldwide, melanoma can strike at any age. Although rates of cure are higher than they used to be, experts often disagree about the best course of treatment and patients face a bewildering array of possibilities—often with precious little time to choose. Drawing on his years as one of the nation’s foremost researchers and specialists in the field of melanoma treatment, Dr. Howard L. Kaufman shares his easy- to-follow, whole-life plan for detecting melanoma early, making informed decisions after a diagnosis, and taking an active role in treatment.
	QuickFACTS Melanoma Skin Cancer: What You Need to Know-NOW by American Cancer Society (Author) This pocket-sized reference covers everything from the risk factors of melanoma skin cancer to the diagnosis procedure to living well after treatment. With greater public awareness, early detection of melanoma skin cancer is on the rise and mortality rates are declining; this medical guide emphasizes that all patients should be well-informed decision makers in planning their own treatment and is updated with the latest patient treatment guidelines. An advanced dictionary of cancer-related terms and a list of critical questions to ask health care administrators are also included.
	From Melanocytes to Melanoma: The Progression to Malignancy by Vincent J. Hearing (Editor), Stanley P. L. Leong (Editor) Leading researchers and clinicians join forces to explain how malignant melanoma develops from its benign precursor cell type. The authors focus on the molecular mechanisms involved in melanogenesis, in the malignant transformation of melanocytes, and in the further progression of primary melanomas into invasive and metastatic melanomas. They also review recent advances in our understanding of the basic biology of melanocytes and the development, migration, and differentiation of melanoblasts into melanocytes. The book provides an up-to-date understanding of the progressive mechanisms of oncological development in malignant melanoma, a likely model of malignant progress for other types of cancer, and the ongoing development of novel therapeutics.
	Unforeseen Consequences: A Physician's Personal Triumph Over Advanced Melanoma by Nicholas Steiner (Author) Dr. Nicholas Steiner is a Park Avenue internist in his mid-forties. He has a successful medical practice, a stable marriage with a home in the suburbs and enjoys good health. But when he develops melanoma, a potentially fatal type of cancer, everything ch
	What You Need To Know About: Melanoma and Other Skin Cancers This booklet is for people diagnosed with the most common types of skin cancer like Melanoma, Basal cell skin cancer and Squamous cell skin cancer. Skin cancer is the most common type of cancer in the United States. Each year, more than 68,000 Americans are diagnosed with melanoma, and another 48,000 are diagnosed with an early form of the disease that involves only the top layer of skin. Also, more than 2 million people are treated for basal cell or squamous cell skin cancer each year. Basal cell skin cancer is several times more common than squamous cell skin cancer. Learning about medical care for skin cancer can help you take an active part in making choices about your care. This booklet tells about, diagnosis and staging, treatment, follow-up care, how to...
	Malignant Melanoma: Your Way Forward by Abaco Publishing You will never cure anything if you don’t do something about the underlying cause. This applies to every illness including malignant melanoma. In my book ‘Malignant Melanoma – Your way Forward’ I explain why it may have developed, giving you something to do to change the underlying causes and bring things under control. It could be related to a vaccination, being burned in the sun, associated with bad eating habits, a poor immune system, infections, too many antibiotics, toxic chemicals, geopathic stress and certainly stresses of everyday life affecting your emotions. When cancer declares itself, it could have been developing for ten or fifteen years. All of this is explained to you in detail as though you are with me in my consulting room. I then give ideas on how to change your...